Skip to main content

BBS-Bioactive Bone Substitutes Plc has renewed a capital facility with RiverFort Global Opportunities PCC

Written by Customer Service on . Posted in Public Companies.

BBS-Bioactive Bone Substitutes Plc, Company announcement, Inside information, 31 March 2023 at 7.45 p.m. (EEST)

BBS-Bioactive Bone Substitutes Plc has renewed a capital facility with RiverFort Global Opportunities PCC

BBS-Bioactive Bone Substitutes Plc (“BBS, “Company”) has today renewed the company’s capital facility agreement announced on September 30, 2021 with Riverfort Global Opportunities PCC (“RiverFort”) and the maturity dates of repayment installments have been extended by one year. For the first installment the maturity date is 31 March 2024 (previously 31 March 2023) and for the second it is 22 August 2024 (previously 22 August 2024). Key commercial terms and conditions remain unchanged. The reference price on the outstanding amount is recalculated according to the agreement terms to be now EUR 1.008 per share. Consequently, the fixed conversion price shall be EUR 1.4113 per share.

The issuer shall issue 177,140 warrants to Riverfort with the exercise price of EUR 1.4113 per share and expiry date of March 2027.

RiverFort has decided to convert EUR 50,000 of the loan capital into BBS shares, and in addition, a contract renewal fee (5% of the loan capital, equal to EUR 25,000) will be settled in shares. Consequently, BBS issued RiverFort a total of 84,303 company shares at a price of EUR 0.8897 per share. After the transfers, BBS will hold 425,220 treasury shares.

“Our close cooperation with RiverFort continues, and the new arrangement strengthens our company’s working capital and supports the company’s goal of receiving the CE marking,” says Ilkka Kangasniemi, CEO of BBS.

For more information, please contact:

Ilkka Kangasniemi, CEO,+358 40 7080307,
ilkka.kangasniemi@bbs-artebone.fi

Certified Advisor: Nordic Certified Adviser AB,+46 70 551 67 29,
info@certifiedadviser.se

BBS in brief

BBS-Bioactive Bone Substitutes Plc is a Finnish orthobiology company whose core competence is the development, commercialization and manufacture of easy-to-use bone implants that promote bone formation and healing. Bone substitutes, i.e. implants, are intended for the treatment of various bone damage, bone healing problems and bone diseases instead of autologous and bank bone grafts. BBS aims to become one of the leading players in the field of bioactive implants intended for bone healing problems. The company’s head office is located in Oulu, and it employs 20 people.

BBS was founded in 2003, and the company has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.